Decibel Therapeutics Inc (OQ:DBTX)

Business Focus: Biotechnology & Medical Research

INK Ultra Money Free

Latest 10 SEC filings (by transaction date) for DBTX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 24th, 2021
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 19/21 Feb 19/21 Exter Neil Indirect Ownership Common Stock Form 3/A : Amendment of a previous Form 3    
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Series D Preferred Stock C - Conversion -1,737,619  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Series C Preferred Stock C - Conversion -3,125,000  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Series A Preferred Stock C - Conversion -7,119,850  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Common Stock P - Open market or private purchase 150,000 $18.00
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Common Stock C - Conversion 327,852  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Common Stock C - Conversion 247,324  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Common Stock C - Conversion 458,487  
Feb 18/21 Feb 17/21 Longevity Fund 2 LP Direct Ownership Convertible Series C Preferred Stock C - Conversion -79,143  
Feb 18/21 Feb 17/21 Longevity Fund 2 LP Direct Ownership Common Stock C - Conversion 79,143  
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for DBTX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 24th, 2021
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Series D Preferred Stock C - Conversion -1,737,619  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Series C Preferred Stock C - Conversion -3,125,000  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Series A Preferred Stock C - Conversion -7,119,850  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Common Stock P - Open market or private purchase 150,000 $18.00
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Common Stock C - Conversion 327,852  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Common Stock C - Conversion 247,324  
Feb 19/21 Feb 17/21 Glaxosmithkline Plc Indirect Ownership Common Stock C - Conversion 458,487  
Feb 19/21 Feb 17/21 Orbimed Advisors Llc Indirect Ownership Series D Preferred Stock C - Conversion -1,158,412  
Feb 19/21 Feb 17/21 Orbimed Advisors Llc Indirect Ownership Series D Preferred Stock C - Conversion -1,737,619  
Feb 19/21 Feb 17/21 Orbimed Advisors Llc Indirect Ownership Series D Preferred Stock C - Conversion -14,480,162  
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $DBTX

Competitors

Competitors with Recent Insider Filings
Moderna (OQ:MRNA)
Crispr Therapeutics AG (OQ:CRSP)
Revolution Medicines (OQ:RVMD)

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.